These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 26762778)

  • 21. Neuronal-specific impairment of heparan sulfate degradation in Drosophila reveals pathogenic mechanisms for Mucopolysaccharidosis type IIIA.
    Webber DL; Choo A; Hewson LJ; Trim PJ; Snel MF; Hopwood JJ; Richards RI; Hemsley KM; O'Keefe LV
    Exp Neurol; 2018 May; 303():38-47. PubMed ID: 29408731
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enzyme-replacement therapy from birth delays the development of behavior and learning problems in mucopolysaccharidosis type IIIA mice.
    Gliddon BL; Hopwood JJ
    Pediatr Res; 2004 Jul; 56(1):65-72. PubMed ID: 15128919
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Correction of murine mucopolysaccharidosis type IIIA central nervous system pathology by intracerebroventricular lentiviral-mediated gene delivery.
    McIntyre C; Derrick-Roberts AL; Byers S; Anson DS
    J Gene Med; 2014; 16(11-12):374-87. PubMed ID: 25418946
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Axonal dystrophy in the brain of mice with Sanfilippo syndrome.
    Beard H; Hassiotis S; Gai WP; Parkinson-Lawrence E; Hopwood JJ; Hemsley KM
    Exp Neurol; 2017 Sep; 295():243-255. PubMed ID: 28601604
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Robust LC-MS/MS methods for analysis of heparan sulfate levels in CSF and brain for application in studies of MPS IIIA.
    Makower Å; Arnelöf E; Andersson T; Edlund PO; Gustavsson S; Janson J; Gelius SS; Tjernberg A
    Bioanalysis; 2019 Aug; 11(15):1389-1403. PubMed ID: 31490106
    [No Abstract]   [Full Text] [Related]  

  • 26. Enzyme Replacement Therapy for Mucopolysaccharidosis IIID using Recombinant Human α-
    Wang F; Moen DR; Sauni C; Kan SH; Li S; Le SQ; Lomenick B; Zhang X; Ekins S; Singamsetty S; Wood J; Dickson PI; Chou TF
    Mol Pharm; 2021 Jan; 18(1):214-227. PubMed ID: 33320673
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term safety and clinical outcomes of intrathecal heparan-N-sulfatase in patients with Sanfilippo syndrome type A.
    Wijburg FA; Heap F; Rust S; de Ruijter J; Tump E; Marchal JP; Nestrasil I; Shapiro E; Jones SA; Alexanderian D
    Mol Genet Metab; 2021 Dec; 134(4):317-322. PubMed ID: 34600820
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gastrointestinal pathology in a mouse model of mucopolysaccharidosis type IIIA.
    Roberts AL; Howarth GS; Liaw WC; Moretta S; Kritas S; Lymn KA; Yazbeck R; Tran C; Fletcher JM; Butler RN; Byers S
    J Cell Physiol; 2009 May; 219(2):259-64. PubMed ID: 19170061
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of a C57BL/6 congenic mouse strain of mucopolysaccharidosis type IIIA.
    Crawley AC; Gliddon BL; Auclair D; Brodie SL; Hirte C; King BM; Fuller M; Hemsley KM; Hopwood JJ
    Brain Res; 2006 Aug; 1104(1):1-17. PubMed ID: 16828069
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correction of mucopolysaccharidosis type IIIA somatic and central nervous system pathology by lentiviral-mediated gene transfer.
    McIntyre C; Byers S; Anson DS
    J Gene Med; 2010 Sep; 12(9):717-28. PubMed ID: 20683858
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improvement in behaviour after substrate deprivation therapy with rhodamine B in a mouse model of MPS IIIA.
    Roberts AL; Rees MH; Klebe S; Fletcher JM; Byers S
    Mol Genet Metab; 2007; 92(1-2):115-21. PubMed ID: 17681480
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SGSH gene transfer in mucopolysaccharidosis type IIIA mice using canine adenovirus vectors.
    Lau AA; Hopwood JJ; Kremer EJ; Hemsley KM
    Mol Genet Metab; 2010 Jun; 100(2):168-75. PubMed ID: 20231109
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intracisternal enzyme replacement therapy in lysosomal storage diseases: routes of absorption into brain.
    Jolly RD; Marshall NR; Perrott MR; Dittmer KE; Hemsley KM; Beard H
    Neuropathol Appl Neurobiol; 2011 Jun; 37(4):414-22. PubMed ID: 21175738
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intracerebroventricular dosing of N-sulfoglucosamine sulfohydrolase in mucopolysaccharidosis IIIA mice reduces markers of brain lysosomal dysfunction.
    Magat J; Jones S; Baridon B; Agrawal V; Wong H; Giaramita A; Mangini L; Handyside B; Vitelli C; Parker M; Yeung N; Zhou Y; Pungor E; Slabodkin I; Gorostiza O; Aguilera A; Lo MJ; Alcozie S; Christianson TM; Tiger PMN; Vincelette J; Fong S; Gil G; Hague C; Lawrence R; Wendt DJ; Lebowitz JH; Bunting S; Bullens S; Crawford BE; Roy SM; Woloszynek JC
    J Biol Chem; 2022 Dec; 298(12):102625. PubMed ID: 36306823
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Functional correction of CNS lesions in an MPS-IIIA mouse model by intracerebral AAV-mediated delivery of sulfamidase and SUMF1 genes.
    Fraldi A; Hemsley K; Crawley A; Lombardi A; Lau A; Sutherland L; Auricchio A; Ballabio A; Hopwood JJ
    Hum Mol Genet; 2007 Nov; 16(22):2693-702. PubMed ID: 17725987
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of heparin cofactor II-thrombin complex as a biomarker on blood spots from mucopolysaccharidosis I, IIIA and IIIB mice.
    Langford-Smith K; Arasaradnam M; Wraith JE; Wynn R; Bigger BW
    Mol Genet Metab; 2010 Mar; 99(3):269-74. PubMed ID: 19926322
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glycosaminoglycan levels and structure in a mucopolysaccharidosis IIIA mice and the effect of a highly secreted sulfamidase engineered to cross the blood-brain barrier.
    Maccari F; Sorrentino NC; Mantovani V; Galeotti F; Fraldi A; Volpi N
    Metab Brain Dis; 2017 Feb; 32(1):203-210. PubMed ID: 27585464
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Heterologous HSPC Transplantation Rescues Neuroinflammation and Ameliorates Peripheral Manifestations in the Mouse Model of Lysosomal Transmembrane Enzyme Deficiency, MPS IIIC.
    Pan X; Caillon A; Fan S; Khan S; Tomatsu S; Pshezhetsky AV
    Cells; 2024 May; 13(10):. PubMed ID: 38786099
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fluoxetine ameliorates mucopolysaccharidosis type IIIA.
    Capuozzo A; Montefusco S; Cacace V; Sofia M; Esposito A; Napolitano G; Nusco E; Polishchuk E; Pizzo MT; De Risi M; De Leonibus E; Sorrentino NC; Medina DL
    Mol Ther; 2022 Apr; 30(4):1432-1450. PubMed ID: 35121108
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early disease course is unaltered in mucopolysaccharidosis type IIIA (MPS IIIA) mice lacking α-synuclein.
    Soe K; Beard H; Neumann D; Trim PJ; Duplock S; Snel MF; Hopwood JJ; Hemsley KM
    Neuropathol Appl Neurobiol; 2019 Dec; 45(7):715-731. PubMed ID: 30907009
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.